NCT01712204View on ClinicalTrials.gov

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Gout Flares
Interventions
DRUG

Placebo

Placebo Capsule BID for 16 Weeks

DRUG

AC-201

AC-201 50mg Capsule BID for 16 Weeks

DRUG

Febuxostat

Febuxostat 80 mg QD for 16 Weeks

Trial Locations (1)

Unknown

Veterans General Hospital, Taipei

All Listed Sponsors
lead

TWi Biotechnology, Inc.

INDUSTRY

NCT01712204 - A Proof-of-Concept Study of AC-201 to Prevent Gout Flares | Biotech Hunter | Biotech Hunter